General/Multifunctional Contrast Agents TRIZ Cases

Coumarin-modified androgen compounds block backdoor DHT synthesis and suppress AR-V7-positive prostate cancer cell growth.

Stable macrocyclic gadolinium chelates enable liver-specific CT and MRI imaging with high relaxivity, tolerability, and complete excretion.

Redox-activated fluorescent nanoparticles target CD206-positive TAMs to distinguish metastatic from normal lymph nodes in breast cancer imaging.

An FGE-activated sulfatase tag creates a defined antibody attachment site, avoiding heterogeneous drug loading and improving dosing consistency.

Polyfunctional dendritic carriers improve agent targeting while stabilizing nanodroplets, microbubbles, and nanoemulsions for imaging and therapy.

DOR-targeted conjugates concentrate immunotherapy and imaging in tumors, boosting immune response while lowering systemic toxicity.

Fully human CEACAM1 antibodies improve tumor selectivity and NK cell killing while reducing toxicity to normal tissues.

Acid-cleavable PSMA conjugates target prostate lesions and limit off-target toxicity.

A liver-targeted dual-modal probe combines fluorescence and photoacoustic imaging to visualize reactive oxygen species in hepatic tissue.

Heterocyclic imaging agents penetrate neuronal cells and oxidize within mitochondria to enable PET detection of reactive oxygen species.

Zwitterionic polymeric coatings encapsulate magnetic nanoparticles and quantum dots to provide colloidal stability.

A monoclonal antibody isolates patient-derived B cells to detect tumor-associated antigens with high binding affinity.

Biomimetic polymeric particles use naturally derived cell membranes to mimic natural cell size and shape for precise drug delivery.

Modified peptide urea derivatives improve PSMA-targeted radiopharmaceutical delivery, resolving suboptimal pharmacokinetics in prostate cancer treatment.

Engineered immune cells express detectable markers upon binding to tumor antigens, reducing false positives from conventional serum markers.

A liposome contrast agent delivers radiolabeled substances to tumors via a specific lipid composition.

A synthetic library of chimeric VNAR molecules enables high-throughput selection of antigen-specific binders without animal immunization.

A polymer coating releases a diagnostic agent upon enzymatic cleavage of a specific site.

Replacing invasive biopsies, fluorescent PAMAM dendrimers bind PSMA-expressing cells to enable precise optical and photoacoustic detection of prostate cancer.

Lipophilic metal ion complexes cross the blood-brain barrier to enable direct measurement of cation metabolism in the central nervous system.

A ferrofluid-filled shell distorts magnetic fields to track medical devices, reducing anatomical damage from rigid sensors.

Cysteine-modified synaptotagmin I C2A domain enables homogeneous cell death detection by resolving renal clearance and binding affinity trade-offs.

Composite biopsy markers resolve imaging modality conflicts by combining gas-filled pores for ultrasound with calcifying cores for X-ray and MRI localization.

Anti-B7-H3 Gp2 scaffolds use segmented variable domains to penetrate tumors while maintaining high binding affinity.

Multidentate aza ligands increase relaxivity by accommodating two inner-sphere water molecules while maintaining thermodynamic stability.

Whole-body molecular imaging detects toxicity-induced tissue injury early, reducing resource loss in drug discovery.

Cleavable protecting groups mask amine charges on protein conjugates, preventing blood adhesion while enabling endosomal escape for intracellular delivery.

Composite polymer scaffolds extend circulation time while maintaining high image contrast in gadolinium-based MRI diagnostics.

Covalent oligosaccharide tags prevent hydrophobic payload aggregation in antibody-drug conjugates, enabling higher drug-to-antibody ratios.

A perfluoroaryl conjugation strategy enables rapid 18F radiolabeling of biomolecular agents under mild conditions.

Light-activated caged peptides resolve non-specific uptake by restricting cell penetration to illuminated target sites, improving treatment specificity.

Engineered antibodies eliminate FcγR interactions to selectively activate TNFR2, resolving unwanted immune suppression in autoimmune treatments.

Chelating moieties enable rapid copper-free click chemistry conjugation of 18F metal complexes to peptides, eliminating time-consuming HPLC purification steps.

Composite stabilizing layers with specific saturated and unsaturated fatty acid ratios improve microvesicle stability in physiological environments.

Iron-doped hydroxyapatite gains intrinsic magnetism to guide scaffold placement and drug release, replacing invasive mechanical fixing systems.

Capping substituents neutralize free reactive groups on polyvalent linker-bound aggregates to ensure consistent in vivo behavior.

Perfluoroaryl prosthetic groups enable rapid 18F substitution under mild conditions, preserving biomolecule activity lost in harsh direct labeling.

Segmented homing agents enable precise intra-pump thrombus detection without increasing diagnostic tool complexity.

Segmented Fcab-drug conjugates merge Fc fragments with antigen-binding domains to resolve the trade-off between molecular size and half-life.

A gadolinium chelate complex formed by chelating gadolinium ions with high-molecular polymers to enhance longitudinal relaxation rates.